Clinical and demographic characteristics for the analysis cohort of 4886 participants by race
| . | Asian (n = 1103) . | Black (n = 670) . | White (n = 3113) . | P* . |
|---|---|---|---|---|
| Clinical characteristics† | ||||
| Warfarin dose, mg/wk | 21 (17.5-28.0) | 40 (30.0-52.5) | 31.5 (21.0-42.0) | < .001 |
| INR achieved | 2.2 (2.0-2.5) | 2.4 (2.2-2.7) | 2.5 (2.2-2.6) | < .001 |
| Height, cm | 161.0 (154.8-167.9) | 170.2 (162.6- 179.0) | 172.7 (163.0-178.0) | < .001 |
| Weight, kg | 60.0 (53.2-69.3) | 87.3 (74.6-104.5) | 82.1 (71.2-95.3) | < .001 |
| Demographic characteristics‡ | ||||
| Male | 596 (54) | 295 (44) | 1899 (61) | < .001 |
| Age | .001 | |||
| 10-19 y | 2 (0.3) | 2 (0.3) | 6 (0.2) | |
| 20-29 y | 15 (1.4) | 21 (3.1) | 69 (2.2) | |
| 30-39 y | 49 (4.5) | 50 (7.5) | 107 (3.4) | |
| 40-49 y | 153 (14.1) | 111 (16.6) | 234 (7.5) | |
| 50-59 y | 247 (22.8) | 163 (24.3) | 524 (16.8) | |
| 60-69 y | 328 (30.3) | 154 (23.0) | 709 (22.8) | |
| 70-79 y | 242 (22.4) | 120 (17.9) | 961 (30.9) | |
| 80-89 y | 45 (4.2) | 43 (6.4) | 478 (15.4) | |
| 90 y and older | 1 (0.1) | 6 (0.9) | 25 (0.8) | |
| Concurrent CYP2C9 inducers | 4 (0.3) | 14 (2.1) | 38 (1.2) | .001 |
| Concurrent amiodarone | 14 (1.3) | 33 (5.0) | 198 (6.4) | < .001 |
| . | Asian (n = 1103) . | Black (n = 670) . | White (n = 3113) . | P* . |
|---|---|---|---|---|
| Clinical characteristics† | ||||
| Warfarin dose, mg/wk | 21 (17.5-28.0) | 40 (30.0-52.5) | 31.5 (21.0-42.0) | < .001 |
| INR achieved | 2.2 (2.0-2.5) | 2.4 (2.2-2.7) | 2.5 (2.2-2.6) | < .001 |
| Height, cm | 161.0 (154.8-167.9) | 170.2 (162.6- 179.0) | 172.7 (163.0-178.0) | < .001 |
| Weight, kg | 60.0 (53.2-69.3) | 87.3 (74.6-104.5) | 82.1 (71.2-95.3) | < .001 |
| Demographic characteristics‡ | ||||
| Male | 596 (54) | 295 (44) | 1899 (61) | < .001 |
| Age | .001 | |||
| 10-19 y | 2 (0.3) | 2 (0.3) | 6 (0.2) | |
| 20-29 y | 15 (1.4) | 21 (3.1) | 69 (2.2) | |
| 30-39 y | 49 (4.5) | 50 (7.5) | 107 (3.4) | |
| 40-49 y | 153 (14.1) | 111 (16.6) | 234 (7.5) | |
| 50-59 y | 247 (22.8) | 163 (24.3) | 524 (16.8) | |
| 60-69 y | 328 (30.3) | 154 (23.0) | 709 (22.8) | |
| 70-79 y | 242 (22.4) | 120 (17.9) | 961 (30.9) | |
| 80-89 y | 45 (4.2) | 43 (6.4) | 478 (15.4) | |
| 90 y and older | 1 (0.1) | 6 (0.9) | 25 (0.8) | |
| Concurrent CYP2C9 inducers | 4 (0.3) | 14 (2.1) | 38 (1.2) | .001 |
| Concurrent amiodarone | 14 (1.3) | 33 (5.0) | 198 (6.4) | < .001 |